PrEP Learning Network: Addressing Intimate Partner Violence in PrEP Services - Shared screen with speaker view
Who can see your viewing activity?
Hi all Samuel Uganda
Jane Thiomi Kenya
From Fikile Mashaba: What are the dangers of not adhering to PrEP?
@Fikile: The danger of not adhering to PrEP is acquiring HIV infection; presumably if they are taking PrEP then they are at risk of infection. They may be at even more risk during COVID-19 epidemic given the isolation, lack of access to support, and potential for increased IPV.
@Fikile - primarily the lack of effectiveness if PrEP isn't taken daily and therefore making the at-risk individual more susceptible to acquiring HIV. Or did you mean in a different sense? Please clarify if this doesn't answer your question.
From Michael Gaitho: what are the steps for conducting RE
No sound from the presenter
How do we addresses issues of support where the client will not disclose/accept assistance/ take up PrEP because of economic dependence on the perpetrator? This is also the main reason many of our AGYW (Eswatini) stay with their partners.
We can go to the next presenter
@Kristine and all- RE is routine enquiry
She is trying to reconnect
How can a client be motivated to continue PrEP when they face side effects?
@Maria Jose Alcala- yes, all presentations (and additional resources on this topic) will be available on PrEPWatch post call
Can you call her directly
US: 877 853 5247 (Toll Free) or 888 788 0099 (Toll Free)Brazil: 0 800 282 5751 (Toll Free) or 0 800 878 3108 (Toll Free)Kenya: 800 720 248 (Toll Free) or 0 800 733 310 (Toll Free)Peru: 0 800 76930 (Toll Free) or 0 800 78743 (Toll Free)South Africa: 0 800 008 728 (Toll Free) or 0 800 064 584 (Toll Free)United Kingdom: 0 800 031 5717 (Toll Free) or 0 800 260 5801 (Toll Free)Argentina: 822 345 9889 (Toll Free)Botswana: 00 269 800 280 0101 (Toll Free)Webinar ID: 797 079 504
@Florence Mulenga- side effects often only last a couple of weeks so the initial weeks are important counseling times for new clients. Programs have different ways of tackling this to get clients through this period. Some have specific fact sheets on side effects for clients. Wits RHI wrote a blogpost on this building off the findings from their ACCESS study: https://www.hivsharespace.net/blog/access-prep-blog-series-slaying-side-effects-its-all-about-managing-menace
Since packaging (bottle) is a challenge for some clients, is the manufacturers thinking of changing that?
From Herbert Kadama: Are there no male victims of GBV?
From Barbara Friedland: What are the implications of re-packaging PrEP in terms of Truvada's stability once outside of the bottle?
The presentation focuses on the female partner, what about lessons from the male partners? Floremce from zambia
From Didier Ngoie: I think that for the best success of the IPV, a specific budget will be needed for training and monitoring of activities in the field.
From Herbert Kadama: Doesn't repackaging affect the efficacy of the PrEP drugs
She sounds muffled, not clear.
The latest stability data from Gilead is that Truvada is stable up to 6 weeks maximum outside the original bottle/packaging, as long as it is not exposed to direct sunlight.
Anne, how often do you have to re-evaluate this referral list?
How do you keep the focal points motivated to continue working?
Are the counsellors clinicians or train lay cadre?
Is it possible to share the videos?
Michele Lanham, for women who are at risk of violence, what module do they receive,? do you screen for women who might be undergoing some of violence as a result of PREP use ?
please share the video
please share the video
Yes, the full webinar as well as slide deck will be available on PrEPWatch early next week. Thank you for joining!
Robyn Dayton: firstname.lastname@example.org - she is the person talking about IPV and KPs